Physician
Lebowicz, Joseph
Lebowicz, Joseph was paid $140K by Medicaid between Jan 2018 and Nov 2024, across 23 billing codes. Its largest line is Q5106, Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units — 25% of everything it billed.
33Billing provider infoLEBOWICZ, JOSEPH
BROOKLYN, NY 11229
BROOKLYN, NY 11229
33aNPI1376543959assigned 07/26/2005
33bProvider typeHematology & Oncology Physician
28Total paid$140K
24GClaims17,335
24DCodes billed23
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Hematology & Oncology Physician providers in New York
Rank by total paid#58 of 441
Median peer was paid$9K
This provider vs. median15×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,522 | $10K | |
| 2019 | 3,256 | $19K | |
| 2020 | 3,797 | $22K | |
| 2021 | 4,362 | $38K | |
| 2022 | 3,057 | $33K | |
| 2023 | 1,131 | $15K | |
| 2024incomplete | 210 | $3K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 25% | 546 | 222 | $35K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 22% | 996 | 983 | $30K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 17% | 1,117 | 769 | $24K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 9.6% | 51 | 39 | $13K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.9% | 4,836 | 3,359 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 4.9% | 3,046 | 1,746 | $7K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 4.9% | 95 | 37 | $7K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 3.1% | 188 | 91 | $4K |
| 96367 | 2.1% | 262 | 160 | $3K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.9% | 93 | 93 | $3K |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 1.4% | 354 | 296 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 432 | 293 | $2K |
11 more codes
| 36415 | Collection of venous blood by venipuncture | 1.1% | 3,247 | $2K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 104 | $404.15 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 398 | $261.56 |
| 96401 | <1% | 22 | $152.54 | |
| 80053 | Comprehensive metabolic panel | <1% | 755 | $16.74 |
| 82728 | 0% | 168 | $0.00 | |
| 83550 | 0% | 151 | $0.00 | |
| 82746 | 0% | 106 | $0.00 | |
| 82607 | 0% | 121 | $0.00 | |
| 83540 | 0% | 154 | $0.00 | |
| 84100 | 0% | 93 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.